| Valuation method | Value, £ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 96.90 | -71 |
| Intrinsic value (DCF) | 95.32 | -72 |
| Graham-Dodd Method | 0.40 | -100 |
| Graham Formula | 3.40 | -99 |
Uniphar plc (UPR.L) is a diversified healthcare services company headquartered in Dublin, Ireland, operating across the Republic of Ireland, the UK, and internationally. The company is structured into three key divisions: Commercial & Clinical, Product Access, and Supply Chain & Retail. Uniphar provides outsourced sales, marketing, and distribution services to pharmaco-medical and medical device manufacturers, ensuring efficient product access and supply chain solutions. Its Product Access division specializes in connecting manufacturers with healthcare stakeholders, while the Supply Chain & Retail segment manages wholesale distribution and operates a network of pharmacies under brands like Life, Allcare, and Hickey's. Founded in 1967, Uniphar has grown into a critical player in the healthcare distribution sector, offering specialized services such as medical device distribution, healthcare technology, and data intelligence. With a market cap of approximately £747 million, Uniphar continues to expand its footprint in the competitive medical distribution industry, leveraging its diversified business model to drive growth.
Uniphar plc presents a compelling investment case due to its diversified healthcare services model, which spans commercial, clinical, and retail segments. The company's revenue of £2.77 billion and net income of £64.2 million in the latest fiscal year reflect steady operational performance. With a beta of 0.958, Uniphar exhibits lower volatility compared to the broader market, making it a relatively stable investment in the healthcare sector. However, investors should note the company's total debt of £406 million, which could pose risks in a rising interest rate environment. The dividend yield, supported by a £0.02 per share payout, adds income appeal. Uniphar's strong cash position (£103 million) and operating cash flow (£124 million) provide financial flexibility, but capital expenditures (£79.7 million) indicate ongoing investment needs. Overall, Uniphar's diversified operations and stable cash flow generation make it an attractive mid-cap healthcare play, though debt levels warrant monitoring.
Uniphar plc operates in the highly competitive medical distribution industry, where scale, supply chain efficiency, and customer relationships are critical. The company's competitive advantage lies in its diversified service offerings, spanning commercial, clinical, and retail segments, which provide multiple revenue streams and reduce dependency on any single market. Uniphar's strong presence in Ireland and the UK, combined with its international operations, positions it well against regional and global competitors. Its Product Access division differentiates itself by fostering exclusive partnerships with pharmaceutical manufacturers, ensuring a steady pipeline of high-margin products. However, Uniphar faces intense competition from larger global distributors like McKesson and AmerisourceBergen, which benefit from greater scale and resources. The company's Supply Chain & Retail division competes with regional pharmacy chains and wholesalers, where pricing pressure and regulatory changes can impact margins. Uniphar's ability to integrate technology and data solutions into its operations provides a modern edge, but maintaining this advantage requires continuous investment. Overall, Uniphar's niche focus and diversified model offer resilience, but competing with global giants remains a challenge.